- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02509702
Use of SMSs to Improve Attendance to Cervical Cancer Follow-up Screening
December 28, 2021 updated by: Marianne Andersen
Text Messages to Increase Attendance to Follow-up Cervical Cancer Screening Appointments Among HPV Positive Tanzanian Women (Connected2Care)
This study evaluates the effect of the SMS intervention 'Connected2Care' on the attendance rate to cervical cancer screening follow-up appointments.
Study Overview
Detailed Description
Connected2Care is a non-blinded, multicentre, parallel-group, randomised controlled trial.
Tanzanian Women testing positive to HR HPV at inclusion are randomly assigned in an allocation ratio of 1:1 to the SMS intervention or the control group (standard care).
In a period of 10 months, the intervention group will receive 15 one-directional health educative text messages and SMS-reminders for their appointment.
The total sample size will be 700 with 350 women in each study arm.
Primary outcome is attendance rate for follow-up.
Secondary objectives are cost-effectiveness measured through incremental ratios and knowledge of cervical cancer by a 16-item true/false scale questionnaire at baseline and follow-up.
Study Type
Interventional
Enrollment (Actual)
705
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dar es Salaam, Tanzania, 3592
- Ocean Road Cancer Institute (ORCI)
-
Moshi, Tanzania, 3010
- Kilimanjaro Christian Medical Centre (KCMC)
-
-
Kilimanjaro
-
Moshi, Kilimanjaro, Tanzania
- Mawenzi Regional Referral Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Informed consent
- HPV positive
- Age 25 - 60 years
- Private mobile phone
Exclusion Criteria:
- Pregnant on day of enrolment
- Menstruating on day of enrolment
- Hysterectomy
- Diagnosed with cervical pre-cancer within past 12 months
- Diagnosed with cervical cancer
- Invalid mobile phone number
- Unreachable when trying to convey HPV positive result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Connected to Care
The SMS intervention will consist of 15 text messages that will be sent to the intervention group over a period of 10 months.
There will be two types of text messages: (1) educational text messages; and (2) SMS reminders for the follow-up appointment.
|
10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
|
|
No Intervention: Control
The control group will receive standard care, which is a follow-up appointment at 14 months written on an appointment card.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of SMS intervention on attendance rate to follow-up screening appointment
Time Frame: up to 14 months
|
The effect measure of the intervention is the 14-month follow-up attendance rate for HPV positive women.
The number of women in the intervention group that attend follow-up screening will be compared to the the number of women that attend follow-up screening in the control group.
|
up to 14 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability of text message intervention
Time Frame: Baseline + 2 years Follow-up (likert scale)
|
6-point Likert scale (1: I do not like it at all - 6: I like it very much)
|
Baseline + 2 years Follow-up (likert scale)
|
|
Acceptability of text message intervention
Time Frame: 2 years
|
Qualitative interviews.
Open-ended
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cost-effectiveness of intervention
Time Frame: Baseline + 14 months
|
Incremental cost-effectiveness ratio
|
Baseline + 14 months
|
|
Knowledge of cervical cancer and screening
Time Frame: Baselie + 14 months
|
16 item true-false questionaire
|
Baselie + 14 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Vibeke Rasch, MD, University of Southern Denmark
- Study Chair: Julius Mwaiselage, MD, Ocean Road Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
- Linde DS, Andersen MS, Mwaiselage JD, Manongi R, Kjaer SK, Rasch V. Text messages to increase attendance to follow-up cervical cancer screening appointments among HPV-positive Tanzanian women (Connected2Care): study protocol for a randomised controlled trial. Trials. 2017 Nov 21;18(1):555. doi: 10.1186/s13063-017-2215-x.
- Lokke KF, Rasch V, Mwaiselage J, Gammeltoft T, Linde DS. Acceptability of text messages and knowledge change for cervical cancer screening: a Tanzanian mixed methods study. BMJ Open. 2022 Sep 19;12(9):e058450. doi: 10.1136/bmjopen-2021-058450.
- Linde DS, Andersen MS, Mwaiselage J, Manongi R, Kjaer SK, Rasch V. Effectiveness of One-Way Text Messaging on Attendance to Follow-Up Cervical Cancer Screening Among Human Papillomavirus-Positive Tanzanian Women (Connected2Care): Parallel-Group Randomized Controlled Trial. J Med Internet Res. 2020 Apr 2;22(4):e15863. doi: 10.2196/15863.
- Linde DS, Rasch V, Mwaiselage JD, Gammeltoft TM. Competing needs: a qualitative study of cervical cancer screening attendance among HPV-positive women in Tanzania. BMJ Open. 2019 Feb 27;9(2):e024011. doi: 10.1136/bmjopen-2018-024011.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 17, 2015
Primary Completion (Actual)
October 6, 2019
Study Completion (Actual)
October 6, 2019
Study Registration Dates
First Submitted
June 15, 2015
First Submitted That Met QC Criteria
July 25, 2015
First Posted (Estimate)
July 28, 2015
Study Record Updates
Last Update Posted (Actual)
December 29, 2021
Last Update Submitted That Met QC Criteria
December 28, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Connected2Care
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Tata Memorial HospitalMahidol University; Juntendo University; Gunma University; Chiang Mai University...RecruitingStage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018 | Stage IB Cervical Cancer FIGO 2018India, Japan, Thailand
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
Qi ZhouNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
Clinical Trials on Connected to Care
-
The Cleveland ClinicThe Surgical CompanyCompletedHeat Transfer by Clinical Warming DevicesUnited States
-
University Hospital, GrenobleEFCR Department and Sleep Laboratory, Grenoble Alpes University Hospital; Pneumology... and other collaboratorsRecruitingSleep Apnea, Obstructive | Chronic Obstructive Pulmonary DiseaseFrance
-
University Medical Center GroningenCompleted
-
Stanford UniversityCompletedHypertension | Electronic Health Record | Digital HealthUnited States
-
Medtronic DiabetesCompleted
-
Aleva Neurotherapeutics SACompletedParkinson's Disease | Essential TremorSwitzerland
-
University of Santiago de CompostelaMozo Grau S.A.Active, not recruitingPeriimplantitis | Periimplant Bone Loss | Marginal Periimplant Bone LevelSpain
-
University of OttawaCanadian Institutes of Health Research (CIHR); Ottawa Hospital Research InstituteActive, not recruiting
-
Beni-Suef UniversityRecruitingAsthmatic Patients | Aerosol Generating Procedure | MDIEgypt
-
Medtronic DiabetesCompletedType 1 Diabetes Mellitus | Type2 Diabetes MellitusUnited States